Pacira Pharmaceuticals Inc (NASDAQ:PCRX) 2017 Q2 Sentiment Change

November 7, 2017 - By Vivian Park

 Pacira Pharmaceuticals Inc (NASDAQ:PCRX)  2017 Q2 Sentiment Change

Sentiment for Pacira Pharmaceuticals Inc (NASDAQ:PCRX)

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) institutional sentiment increased to 1.62 in 2017 Q2. Its up 0.45, from 1.17 in 2017Q1. The ratio is more positive, as 110 investment managers increased and opened new equity positions, while 68 cut down and sold positions in Pacira Pharmaceuticals Inc. The investment managers in our partner’s database now have: 39.35 million shares, down from 39.78 million shares in 2017Q1. Also, the number of investment managers holding Pacira Pharmaceuticals Inc in their top 10 equity positions increased from 1 to 3 for an increase of 2. Sold All: 23 Reduced: 45 Increased: 73 New Position: 37.

Pacira Pharmaceuticals, Inc. is a holding company. The company has market cap of $1.44 billion. The Firm is a pharmaceutical firm focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. It currently has negative earnings. The Company’s lead product candidate is EXPAREL , which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia.

About 400,622 shares traded. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has risen 12.40% since November 7, 2016 and is uptrending. It has underperformed by 4.30% the S&P500.

Daruma Capital Management Llc holds 3.19% of its portfolio in Pacira Pharmaceuticals Inc for 1.12 million shares. Healthcor Management L.P. owns 1.79 million shares or 3.09% of their US portfolio. Moreover, Venbio Select Advisor Llc has 2.81% invested in the company for 465,818 shares. The New York-based 40 North Management Llc has invested 2.73% in the stock. Great Point Partners Llc, a Connecticut-based fund reported 300,000 shares.#img1#

Since January 1, 0001, it had 0 buys, and 9 selling transactions for $2.59 million activity.

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Ratings Coverage

Ratings analysis reveals 58% of Pacira Pharmaceuticals’s analysts are positive. Out of 19 Wall Street analysts rating Pacira Pharmaceuticals, 11 give it “Buy”, 1 “Sell” rating, while 7 recommend “Hold”. The lowest target is $31 while the high is $113. The stock’s average target of $57.88 is 61.68% above today’s ($35.8) share price. PCRX was included in 66 notes of analysts from July 28, 2015. The firm has “Neutral” rating given on Monday, August 21 by Janney Capital. Mizuho maintained Pacira Pharmaceuticals Inc (NASDAQ:PCRX) rating on Tuesday, July 25. Mizuho has “Buy” rating and $5400 target. Wedbush maintained it with “Buy” rating and $8700 target in Tuesday, July 25 report. The rating was initiated by Mizuho with “Buy” on Tuesday, April 19. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, July 25 report. The firm has “Buy” rating by Piper Jaffray given on Tuesday, July 25. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) earned “Hold” rating by Brean Capital on Friday, July 1. The stock has “Buy” rating by Bank of America on Wednesday, October 4. Jefferies maintained it with “Buy” rating and $59.0 target in Tuesday, September 5 report. On Thursday, October 19 the stock rating was maintained by Needham with “Buy”.

More news for Pacira Pharmaceuticals Inc (NASDAQ:PCRX) were recently published by: Globenewswire.com, which released: “Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement” on October 25, 2017. Nasdaq.com‘s article titled: “Pacira Pharmaceuticals Becomes Oversold (PCRX)” and published on October 18, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.